Roble Belko & Company’s Thermo Fisher Scientific TMO Stock Holding History

Roble Belko & Company’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Hold	71	–	–	﹤0.01%	232
2026 Q1	$35K	Sell	71 -172	-71%	-$93.3K	﹤0.01%	232
2025 Q4	$141K	Buy	243 +172	+242%	+$97.3K	0.02%	144
2025 Q3	$34K	Hold	71	–	–	﹤0.01%	196
2025 Q2	$29K	Hold	71	–	–	﹤0.01%	211
2025 Q1	$35K	Hold	71	–	–	0.01%	190
2024 Q4	$37K	Hold	71	–	–	0.01%	186
2024 Q3	$44K	Hold	71	–	–	0.01%	170
2024 Q2	$39K	Hold	71	–	–	0.01%	178
2024 Q1	$41K	Sell	71 -50	-41%	-$28.1K	0.01%	183
2023 Q4	$64K	Hold	121	–	–	0.01%	150
2023 Q3	$61K	Hold	121	–	–	0.01%	141
2023 Q2	$63K	Hold	121	–	–	0.01%	133
2023 Q1	$70K	Hold	121	–	–	0.01%	139
2022 Q4	$67K	Hold	121	–	–	0.01%	143
2022 Q3	$61K	Hold	121	–	–	0.01%	144
2022 Q2	$66K	Sell	121 -22	-15%	-$12.1K	0.02%	139
2022 Q1	$84K	Buy	143 +72	+101%	+$41.4K	0.02%	142
2021 Q4	$47K	Hold	71	–	–	0.01%	164
2021 Q3	$41K	Hold	71	–	–	0.01%	158
2021 Q2	$36K	Hold	71	–	–	0.01%	175
2021 Q1	$32K	Buy	71 +64	+914%	+$30.5K	0.01%	173
2020 Q4	$3K	Hold	7	–	–	﹤0.01%	279
2020 Q3	$3K	Buy	+7	New	+$2.89K	﹤0.01%	282

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Roble Belko & Company's TMO Position: Q2 2026 in Review

Roble Belko & Company held its Thermo Fisher Scientific (TMO) position steady in Q2 2026 at 71 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #232.

Roble Belko & Company first reported a position in TMO in Q3 2020 and has held it in 24 quarters since. The position peaked at $141K in Q4 2025. 2,617 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Roble Belko & Company held 71 shares of Thermo Fisher Scientific worth $36K as of Q2 2026.
Roble Belko & Company left its Thermo Fisher Scientific share count unchanged in Q2 2026.
Thermo Fisher Scientific made up ﹤0.01% of Roble Belko & Company's portfolio in Q2 2026, its #232 holding.
Roble Belko & Company first reported a position in Thermo Fisher Scientific in Q3 2020 and has held it in 24 quarters since.
Roble Belko & Company's Thermo Fisher Scientific position peaked at $141K in Q4 2025.
2,617 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.